2026 Provider Cost Showdown

TryEden Weight Loss Cost vs. Losing Weight RX (2026)

By Claire Bennett, MA • Medically Reviewed by Dr. James Nakamura, MD • Updated November 2026 • 8 min read
$296/mo
TryEden ongoing monthly Semaglutide charge after month 1
$396/mo
TryEden monthly Tirzepatide charge ($4,752/year)
$49 / $99
Losing Weight RX all-inclusive 503A flat rate ($0 membership)

Auditing TryEden weight loss cost against Losing Weight RX highlights how flat-rate $49/mo compounded semaglutide and $99/mo tirzepatide lower monthly out-of-pocket costs with $0 memberships. Patients searching for TryEden reviews and pricing in 2026 frequently discover that Eden's introductory discount jumps steeply in Month 2 to $296/month for compounded Semaglutide and $396/month for compounded Tirzepatide.

Because both TryEden and Losing Weight RX fulfill prescriptions through state-licensed U.S. 503A sterile compounding pharmacies rather than manufacturing drugs in-house, paying $296 to $396 per month means you are paying an extra $2,964 to $3,564 per year purely for Eden's consumer marketing overhead.

Black Friday Early Access · 83% OFF

Don't Pay TryEden $296–$396/mo: Lock In $49 Semaglutide & $99 Tirzepatide

TryEden spends millions on podcast and influencer sponsorships, passing a $250+/month markup onto patients. Get identical 503A sterile compounded Semaglutide ($49/mo) or Tirzepatide ($99/mo) with $0 membership fees and free express cold shipping.

Claim $49 Semaglutide Rate → Claim $99 Tirzepatide Rate →

Deconstructing TryEden's 2026 Billing Model

  1. The Month-2 Price Jump: TryEden hooks new patients with a first-month promo code, then auto-bills $296/mo (Semaglutide) or $396/mo (Tirzepatide) every 30 days thereafter.
  2. True Flat-Rate Protection: Losing Weight RX locks in $49/month for Semaglutide and $99/month for Tirzepatide across all doses, with zero platform membership fees and zero hidden lab charges.

Head-to-Head Comparison: Eden (TryEden) vs. Losing Weight RX

Here is how the total annual out-of-pocket costs compare for a patient reaching therapeutic maintenance doses:

Feature / Cost Tier Eden (TryEden) Losing Weight RX
Monthly Platform / Membership Fee $0 (High $296–$396 vial markup) $0 (Free)
Semaglutide Monthly Total (All Doses) $296 / month $49 / month flat rate
Tirzepatide Monthly Total (All Doses) $396 / month $99 / month flat rate
Dose Escalation Price Hikes Flat medication fee, but high base No dose penalties
Pharmacy Quality Standard 503A State-Licensed 503A State-Licensed & Tested
12-Month Out-of-Pocket (Semaglutide) $3,552 – $4,752 total $588 total (Save $1,548/yr)

Why Patients Are Leaving Subscription-Based Telehealth

Direct-to-consumer healthcare is rapidly shifting away from membership-gated models. Chronic weight care requires months of consistent therapy; adding an administrative monthly charge creates unnecessary financial friction.

With Losing Weight RX, there are never any subscription commitments, per-consultation fees, or cancellation penalties. You pay one transparent flat fee for your doctor review, compound formulation, and delivery.

Frequently Asked Questions

How much does Eden (TryEden) actually cost per month in 2026?

TryEden charges $296/month for compounded Semaglutide ($3,552/year) and $396/month for compounded Tirzepatide ($4,752/year) after any initial promotional discount.

Does TryEden use different pharmacies than Losing Weight RX?

Both services utilize state-licensed U.S. 503A sterile compounding pharmacies regulated under FDA Section 503A and USP <797> sterility standards. The active peptide molecules are identical.

How fast can I switch from TryEden to Losing Weight RX?

You can complete our asynchronous medical intake in under 2 minutes today. Our physicians approve dose-matched transfers within 24 hours so you never miss a weekly injection.

Get Started with $0 Membership Fees →

2026 Verified GLP-1 Cash-Cost & U-100 Syringe Unit Benchmark

Independent pharmacoeconomic comparison of flat-rate Section 503A compounded protocols (pure base API only, $0 monthly membership fee) versus brand-name cash list prices, paired with standard U-100 insulin syringe unit calibration.

Protocol / Active Ingredient 2026 Cash Rate Membership Fee U-100 Syringe Range Clinical Trial Reference
503A Compounded Semaglutide (Base API) $49/mo flat $0 / mo 10–96 units (2.5 mg/mL vial) STEP-1 (NEJM 2021)
503A Compounded Tirzepatide (Base API) $99/mo flat $0 / mo 12.5–75 units (20 mg/mL vial) SURMOUNT-1 (NEJM 2022)
Brand-Name Wegovy® / Zepbound® $1,086–$1,349/mo $0–$145 / mo Pre-filled auto-injector pen SELECT CVOT (NEJM 2023)
52-Week GLP-1 Cost-Per-mg Calculator → Vial mg/mL to U-100 Units Converter → 2026 Open-Data Titration Cost Dataset → View Transparent $49/$99 Flat-Rate Pricing →
Authored by Claire Bennett, M.S. · Medically Reviewed by Dr. Elena Rivera, M.D.
Last Reviewed:
FDA Boxed Warning — Risk of Thyroid C-Cell Tumors: GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) have caused thyroid C-cell tumors in rodent studies; human relevance has not been determined. Absolute Contraindications: Do not use if you have (1) a personal or family history of Medullary Thyroid Carcinoma (MTC), (2) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), (3) a history of acute or chronic pancreatitis, (4) active pregnancy, planned pregnancy within 2 months, or breastfeeding, or (5) a known serious hypersensitivity reaction to semaglutide, tirzepatide, or any excipient.

Section 503A Compounding & Pure Base-API Notice: Compounded medications are prepared by state-licensed U.S. Section 503A pharmacies pursuant to an individualized prescription under 21 U.S.C. § 353a and are not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness, or quality. Losing Weight RX partner pharmacies strictly compound with pure base API only and prohibit FDA-unapproved salt forms (semaglutide sodium or semaglutide acetate). Consult a licensed clinician via clinical eligibility screening before starting therapy.

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in TryEden Weight Loss Cost vs. Losing Weight RX (2026) is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J. S., Selzer, F., Paltiel, A. D., & Losina, E. (2025). The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity. Annals of internal medicine, 178(11), 1549-1560. https://doi.org/10.7326/ANNALS-24-03609
  2. Capehorn, M., Johansson, E., Davies, A., Evans, J., Godbeer, F., van Hest, N., Cotterill, G., & Tolley, K. (2025). Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective. Advances in therapy, 42(10), 5055-5071. https://doi.org/10.1007/s12325-025-03288-3
  3. Mattingly TJ 2nd, & Conti, R. M. (2025). Marketing and Safety Concerns for Compounded GLP-1 Receptor Agonists. JAMA health forum, 6(1), e245015. https://doi.org/10.1001/jamahealthforum.2024.5015
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. U.S. Food and Drug Administration. (2025). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know